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PAtorvastatin Pretreatment Improves Outcomes in
Patients With Acute Coronary Syndromes Undergoing
Early Percutaneous Coronary Intervention
Results of the ARMYDA-ACS Randomized Trial
Giuseppe Patti, MD, FACC,* Vincenzo Pasceri, MD, PHD, FACC,† Giuseppe Colonna, MD,‡
Marco Miglionico, MD,* Dionigi Fischetti, MD,‡ Gennaro Sardella, MD, FACC,§
Antonio Montinaro, MD,‡ Germano Di Sciascio, MD, FACC, FESC*
Rome and Lecce, Italy
Objectives This study sought to investigate potential protective effects of atorvastatin in patients with acute coronary syn-
dromes (ACS) undergoing percutaneous coronary intervention (PCI).
Background Randomized studies have shown that pretreatment with atorvastatin may reduce periprocedural myocardial infarction
in patients with stable angina during elective PCI; however, this therapy has not been tested in patients with ACS.
Methods A total of 171 patients with non–ST-segment elevation ACS were randomized to pretreatment with atorvastatin
(80 mg 12 h before PCI, with a further 40-mg preprocedure dose [n  86]) or placebo (n  85). All patients
were given a clopidogrel 600-mg loading dose. All patients received long-term atorvastatin treatment thereafter
(40 mg/day). The main end point of the trial was a 30-day incidence of major adverse cardiac events (death,
myocardial infarction, or unplanned revascularization).
Results The primary end point occurred in 5% of patients in the atorvastatin arm and in 17% of those in the placebo
arm (p  0.01); this difference was mostly driven by reduction of myocardial infarction incidence (5% vs. 15%;
p  0.04). Postprocedural elevation of creatine kinase-MB and troponin-I was also significantly lower in the ator-
vastatin group (7% vs. 27%, p  0.001 and 41% vs. 58%, p  0.039, respectively). At multivariable analysis,
pretreatment with atorvastatin conferred an 88% risk reduction of 30-day major adverse cardiac events (odds
ratio 0.12, 95% confidence interval 0.05 to 0.50; p  0.004).
Conclusions The ARMYDA-ACS trial indicates that even short-term pretreatment with atorvastatin may improve outcomes in
patients with ACS undergoing early invasive strategy. These findings may support routine use of high-dose
statins before intervention in patients with ACS. (J Am Coll Cardiol 2007;49:1272–8) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.025h
w
l
e
w
d
v
a
p
o
M
She ARMYDA (Atorvastatin for Reduction of MYocardial
amage During Angioplasty) trial (1) has shown that a 7-day
retreatment with atorvastatin is associated with an 81% risk
eduction of periprocedural myocardial infarction in patients with
table angina undergoing elective percutaneous coronary interven-
ion (PCI); attenuation of endothelial activation may explain this
rotective role at least in part (2). The efficacy of atorvastatin
retreatment in patients with acute coronary syndromes undergo-
ng early PCI has not been investigated. Observational data (3)
rom the *Department of Cardiovascular Sciences, Campus Bio-Medico University,
ome, Italy; †Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy;
Interventional Cardiology Unit, Vito Fazzi Hospital, Lecce, Italy; and the §Department
f Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy.(
Manuscript received February 10, 2007; revised manuscript received February 23,
007, accepted February 23, 2007.ave suggested that patients with acute coronary syndromes who
ere already receiving statins at the time of intervention have a
ower incidence of periprocedural myonecrosis and a better cardiac
vent-free survival at 6 months; however, patients were treated
ith different types of statins, variable doses, and unknown
uration of previous treatment, and those findings have not been
alidated in a randomized trial.
Thus, the ARMYDA study group (1,2,4,5) has performed
randomized, placebo-controlled trial evaluating the effects of
retreatment with a specific statin load on 30-day clinical
utcomes after PCI in patients with acute coronary syndromes.
ethods
tudy population and design. The ARMYDA-ACS
Atorvastatin for Reduction of MYocardial Damage During
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March 27, 2007:1272–8 Atorvastatin Improves PCI Results in ACSngioplasty-Acute Coronary Syndromes) trial is a multi-
enter, randomized, prospective, double-blind clinical trial
erformed in 3 Italian institutions (Campus Bio-Medico
niversity of Rome, Vito Fazzi Hospital of Lecce, and
niversity La Sapienza of Rome) (Fig. 1). Inclusion criteria
ere the presence of a non–ST-segment elevation acute
oronary syndrome (unstable angina or non–ST-segment
levation acute myocardial infarction) sent to early (48 h)
oronary angiography. Exclusion criteria were a ST-
egment elevation acute myocardial infarction; non–ST-
egment elevation acute coronary syndrome with high-risk
eatures warranting emergency coronary angiography (6);
ny increase in liver enzymes (aspartate amino transferases/
lanine amino transferases); left ventricular ejection fraction
30%; renal failure with creatinine 3 mg/dl; history of
iver or muscle disease; or previous or current treatment with
tatins. Between January 3, 2005, and December 21, 2006,
total of 771 patients fulfilling the inclusion criteria were
nitially evaluated; 451 patients were excluded because of
revious or current treatment with statins, 41 for non–ST-
egment elevation acute coronary syndrome requiring emer-
ency invasive approach, 43 because of low ejection fraction,
0 because of contraindications to statin treatment (liver or
uscle disease), and 15 because of renal failure. Eligible
atients (n  191) were randomized to receive placebo or
Figure 1 Study Design of the ARMYDA-ACS Trial
ARMYDA-ACS  Atorvastatin for Reduction of MYocardial Damage During Angiopla
tein; MI  myocardial infarction; NSTE-ACS  non–ST-segment elevation acute cor
revascularization.torvastatin (80-mg loading dose
iven a mean of 12 h before
oronary angiography, with a fur-
her 40-mg dose approximately
h before the procedure). Pa-
ients were assigned to the study
rm using an electronic spread-
heet indicating the group as-
ignment by random numbers;
andomization blocks were created and distributed to the 3
enters. After coronary angiography, 20 patients (10 in each
andomization arm) who did not receive angioplasty were
xcluded from the study (8 were treated medically and 12
ith bypass surgery); thus, 171 patients (86 randomized to
torvastatin and 85 to placebo) with significant coronary
rtery disease deemed responsible for the clinical instability
nd undergoing PCI immediately after diagnostic angiog-
aphy were enrolled and represent the study population.
hysicians performing the procedure and the follow-up
ssessment were not aware of the randomization
ssignment.
All interventions were performed with a standard tech-
ique. According to protocol, patients were pretreated
efore intervention with aspirin (100 mg/day) and clopi-
ogrel (600-mg loading dose at least 3 h before the
cute Coronary Syndromes; CK-MB  creatine kinase-MB; CRP  C-reactive pro-
syndrome; PCI  percutaneous coronary intervention; TVR  target vessel
Abbreviations
and Acronyms
CRP  C-reactive protein
MACE  major adverse
cardiac event
PCI  percutaneous
coronary interventionsty—A
onary
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Atorvastatin Improves PCI Results in ACS March 27, 2007:1272–8rocedure) (4). Glycoprotein IIb/IIIa inhibitors were used
t the operator’s discretion. Before intervention, patients
eceived weight-adjusted intravenous heparin with a target
ctivated clotting time of 300 s in the absence of glyco-
rotein IIb/IIIa inhibitor therapy and 200 to 300 s with
lycoprotein IIb/IIIa. Procedural success was defined as
eduction of stenosis to 30% residual narrowing. After
CI, aspirin (100 mg/day) was continued indefinitely,
hereas clopidogrel (75 mg/day) was administered for at
east 6 months; after intervention, all patients were treated
ith atorvastatin (40 mg/day) irrespective of the initial
andomization assignment.
In all 171 patients, blood samples were collected before
nd at 8 and 24 h after PCI to measure creatine kinase-MB
mass), troponin-I (mass), and myoglobin levels; further
easurements were performed in case of postprocedural
ymptoms suggestive of myocardial ischemia. Levels of
reatine kinase-MB, troponin-I, and myoglobin were de-
ected using the Access 2 immunochemiluminometric assay
Beckman Coulter, Brea, California) (7). Upper limits of
ormal were defined as the 99th percentile of normal
opulation with a total imprecision of 10%, according to
oint European Society of Cardiology/American College of
ardiology guidelines (8). Normal limits were4 ng/ml for
reatine kinase-MB, 0.08 ng/ml for troponin-I, and 80
g/ml for myoglobin. The C-reactive protein (CRP) levels
ere also measured before PCI and at 8 and 24 h after
ntervention. The CRP was assayed by the Kriptor ultra-
ensitive immunofluorescent assay (Brahms, Hennigsdorf/
erlin, Germany), with a detection limit of 0.06 mg/l.
ne-month clinical follow-up was performed by office visit
n all study patients. Each patient gave informed consent to
he study. The study was approved by the institutional
eview boards of the institutions involved. The trial was not
upported by any external source of funding.
nd points. The primary end point of the ARMYDA-
CS trial was occurrence of major adverse cardiac events
MACE) (death, myocardial infarction, target vessel revas-
ularization) from the procedure up to 30 days. In patients
ith normal baseline levels of creatine kinase-MB, myocar-
ial infarction was defined as a postprocedural increase of
reatine kinase-MB 2 times above the upper limit of
ormal, according to the consensus statement of the Joint
uropean Society of Cardiology/American College of Car-
iology Committee for the Redefinition of Myocardial
nfarction for clinical trials on coronary intervention (1,8).
n patients with elevated baseline levels of creatine kinase-
B, myocardial infarction was defined as a subsequent
ncrease of more than 2-fold in creatine kinase-MB from
aseline value (9). Target vessel revascularization included
ypass surgery or repeat PCI of the target vessel(s).
Secondary end points of the study were: 1) any postpro-
edural increase of markers of myocardial injury above upper
imits of normal (creatine kinase-MB, troponin-I, myoglo-
in); and 2) postprocedural variations from baseline CRP
evels in the 2 arms. ttatistics. If an overall incidence of MACE at 30 days of
3% is expected in the placebo arm (4) and, according to the
esults of the original ARMYDA study (1), a 81% risk
eduction of adverse events is hypothesized in the atorva-
tatin arm, a total sample size of 171 patients would provide
0% power to detect this difference with an alpha level of
.05. This expected clinical benefit is similar to that re-
orted in a recent observational study describing a signifi-
antly lower incidence of MACE after PCI for an acute
oronary syndrome in patients already taking statins (odds
atio 0.20) (3). Continuous variables between groups were
ompared by t test for normally distributed values, otherwise
he Mann-Whitney U test was used. Proportions were
ompared by the Fisher exact test when the expected
requency was 5, otherwise the chi-square test (Yates
orrected) was applied. Odds ratios and 95% confidence
ntervals assessing the risk of the primary end point accord-
ng to potential confounding variables were assessed by
ogistic regression. The following parameters were evaluated
rst in a univariate model: age, gender, center of enrollment,
se of beta-blockers, angiotensin-converting enzyme inhib-
tors, glycoprotein IIb/IIIa inhibitors, diabetes, dyslipide-
ia, systemic hypertension, cigarette smoking, left ventric-
lar ejection fraction, type of lesion (A/B1 vs. B2/C),
ultivessel intervention, stent length, stent diameter, use of
irect stenting, duration of balloon inflations, and use of
igh-pressure postdilatation. Variables with a p value0.15
ere then entered into a multivariable logistic regression
nalysis. Event-free survival analysis was performed by the
aplan-Meier method with log-rank test group compari-
on. Results are expressed as mean  SD unless otherwise
pecified. All calculations were performed using SPSS 12.0
SPSS Inc., Chicago, Illinois), and p values0.05 (2-tailed)
ere considered significant.
esults
tudy population. Demographic/clinical and procedural
eatures in the atorvastatin and placebo arms are indicated in
ables 1 and 2, respectively. The 2 groups were similar for
ge, gender, cardiovascular risk factors, clinical presentation,
eft ventricular function, blood creatinine levels, mean time
o angiography, and medical therapy at the time of inter-
ention. Coronary anatomy, lesion type, procedural charac-
eristics, use of drug-eluting stents, diameter and length of
mplanted stents, and periprocedural infusion of glyco-
rotein IIb/IIIa inhibitors were also similar. Of note,
atients receiving IIb/IIIa inhibitors had a significantly
igher prevalence of diabetes mellitus, non–ST-segment
levation myocardial infarction, multivessel PCI, bifurcating
esions, and longer lesion length; these agents were used in
planned manner in 60% and in a bail-out manner in 40%
f patients. Procedural success was obtained in all 171
atients; 4 patients (2 in each group) had no-reflow phe-
omenon, which significantly improved after administration
f intracoronary nitrates and glycoprotein IIb/IIIa inhibi-
ors. No patient had significant (2 mm) side branch
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March 27, 2007:1272–8 Atorvastatin Improves PCI Results in ACSlosure during intervention. An increase above the upper
ormal limit of liver enzymes (aspartate amino transferases/
lanine amino transferases) was observed in 1 patient of the
torvastatin arm after the procedure, in whom the drug was
hen discontinued; however, all patients received the study
ssignment drug (atorvastatin or placebo) before PCI.
rimary end point. The primary end point was evaluated at
0 days (Table 3). The composite primary end point of death,
yocardial infarction, and target vessel revascularization oc-
urred in 5% of patients (4 of 86) in the atorvastatin arm and
n 17% (14 of 85) of those in the placebo arm (p 0.01). The
ncidence of MACE at 1 month was mostly driven by
ostprocedural myocardial infarction (5% vs. 15%, p  0.04).
o patient in either arm died; an abrupt vessel closure caused
y coronary dissection occurred in 1 patient (2%) of the placebo
roup the day after the index procedure and was successfully
reated with re-intervention and implantation of another stent;
his patient had no creatine kinase-MB elevation fulfilling the
riteria for myocardial infarction. Kaplan-Meier curves con-
rmed a significantly better event-free survival at 30 days in the
reatment arm (Fig. 2).
econdary end points. The prevalence of patients with pre-
rocedural elevation of cardiac markers above the upper limit
f normal was similar in the atorvastatin and placebo groups
creatine kinase-MB 5% vs. 8%, p  0.52; troponin-I 35% vs.
3%, p 0.92; myoglobin 29% vs. 26%, p 0.77). After PCI,
he proportion of patients with elevated levels of creatine
inase-MB and troponin-I was significantly lower in the
Main Demographic/Clinical Features in the Ato
Table 1 Main Demographic/Clinical Feature
Variable
Male gender
Age (yrs)
Diabetes mellitus
Systemic hypertension
Hypercholesterolemia
Current smoker
Family history of coronary disease
Previous myocardial infarction
Previous coronary intervention
Previous bypass surgery
Left ventricular ejection fraction (%)
Serum creatinine (mg/dl)
Clinical pattern
Unstable angina
Non–ST-segment elevation myocardial infarction
Mean time to angiography (h)
Multivessel coronary artery disease
Therapy
Aspirin
Clopidogrel
Beta-blockers
ACE inhibitors
Glycoprotein IIb/IIIa inhibitors
Values are given as number of patients (%) or mean  SD.
ACE  angiotensin-converting enzyme.torvastatin arm (creatine kinase-MB 7% vs. 27%, p  0.001; rroponin-I 41% vs. 58%, p  0.039); no difference was
bserved in the prevalence of patients with elevated myoglobin
evels after intervention (45% vs. 42%, p 0.81). Distribution
f creatine kinase-MB and troponin-I levels in the 2 groups is
hown in Figure 3.
The CRP levels at the time of the procedure were not
ignificantly different in the 2 groups before (7.8  18 mg/l
n the atorvastatin vs. 4.8  13 mg/l in the placebo group,
 0.21) or after PCI (10  8 mg/l vs. 7.5  13 mg/l,
 0.13); however, the average percent increase of CRP
evels from baseline was significantly lower in the statin arm
63  114% vs. 147  274%, p  0.01).
ultivariable analysis. Multivariable analysis (Fig. 4)
dentified pretreatment with atorvastatin as a predictor of
ecreased risk of MACE at 30 days (odds ratio 0.12, 95%
onfidence interval 0.05 to 0.50; p  0.004); patients
equiring periprocedural use of glycoprotein IIb/IIIa inhib-
tors had an increased risk of events, as well as those with
eft ventricular ejection fraction 40%. Therapy with beta-
lockers or angiotensin-converting enzyme inhibitors at the
ime of PCI was not associated with risk reduction.
iscussion
he ARMYDA-ACS trial is a randomized trial showing that
hort-term pretreatment with atorvastatin reduces the incidence of
ardiac events in patients with acute coronary syndromes under-
oing early PCI; this benefit is essentially driven by a significant
tin and Placebo Groups
the Atorvastatin and Placebo Groups
torvastatin
(n  86)
Placebo
(n  85) p Value
68 (79) 67 (79) 0.88
64  11 67  10 0.06
25 (29) 28 (33) 0.70
63 (73) 63 (74) 0.96
27 (31) 28 (33) 0.96
27 (31) 18 (21) 0.18
27 (31) 24 (28) 0.78
20 (23) 19 (22) 0.97
9 (10) 9 (11) 0.82
2 (2) 3 (4) 0.99
55  7 54  8 0.38
1.1  0.3 1.1  0.2 1
52 (60) 58 (68) 0.37
34 (40) 27 (32) 0.37
23  12 22  10 0.56
29 (34) 39 (46) 0.14
86 (100) 85 (100) 1
86 (100) 85 (100) 1
26 (30) 23 (27) 0.77
67 (78) 65 (76) 0.97
23 (27) 18 (21) 0.50rvasta
s in
Aeduction of periprocedural myocardial infarction.
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Atorvastatin Improves PCI Results in ACS March 27, 2007:1272–8Previous randomized studies have shown that long-term
herapy with statins improves prognosis in subjects with
ypercholesteremia and in patients with stable coronary
rtery disease (10,11); data on the effects of statins in the
etting of acute coronary syndromes are more limited.
bservational studies on patients with acute myocardial
nfarction have suggested that statin initiation within 24 h is
ssociated with a significantly lower occurrence of early
omplications, a reduced infarct size, and better in-hospital
urvival (12,13). Nonrandomized studies on early use of
tatins in patients with a variety of acute coronary syn-
romes have shown conflicting results; a number of them
14,15) have shown a lower occurrence of cardiovascular
vents, but a recent post-hoc analysis on 12,365 patients has
ndicated no benefit in terms of death, myocardial infarc-
ion, or recurrent ischemia at 90 days (16). Indeed, a recent
eta-analysis evaluating the outcomes for up to 4 months of
atients from 12 randomized trials that compared early
rocedural Features in the Atorvastatin and Placeboups
Table 2 Procedural Features in theAtorvastatin and Placebo Groups
Variable
Atorvastatin
(n  86)
Placebo
(n  85) p Value
Vessel treated
Left main — 1 (1) 0.97
Left anterior descending 51 (50) 54 (49) 0.94
Left circumflex 31 (30) 28 (25) 0.56
Right coronary artery 20 (19) 26 (24) 0.56
Saphenous vein grafts 1 (1) 1 (1) 0.51
Restenotic lesions 1 (1) 2 (2) 0.99
Lesion type B2/C 73 (85) 71 (84) 0.97
Multivessel intervention 17 (20) 25 (29) 0.20
Type of intervention
Balloon only 1 (1) 1 (1) 0.48
Stent 85 (99) 84 (99) 0.48
Bifurcations with kissing balloon 8 (9) 8 (9) 0.81
No. of stents per patient 1.4  0.6 1.5  0.9 0.40
Stent diameter (mm) 3.1  0.4 3.1  0.3 0.90
Total stent length (mm) 16.7  5.7 16.9  5.5 0.82
Use of drug-eluting stents 55 (64) 47 (55) 0.32
Direct stenting 41 (48) 36 (42) 0.59
No. of predilatations 2.1  1.4 2.2  1.7 0.68
Stent deployment pressure (atm) 11.2  4.1 11.6  2.7 0.44
Duration of stent deployment (s) 16  7 16  5 1
Total ischemia 120 s 17 (20) 17 (20) 0.88
Use of postdilatation 12 (14) 22 (26) 0.08
alues are given as number of patients (%) or mean  SD.
ndividual and Combined Outcome Measures of therimary End Point at 30 Days in the Atorva tatinnd Placebo Groups
Table 3
Individual and Combined Outcome Measures of the
Primary End Point at 30 Days in the Atorvastatin
and Placebo Groups
Atorvastatin
(n  86)
Placebo
(n  85) p Value
Death — —
Myocardial infarction 4 (5) 13 (15) 0.04
Target vessel revascularization — 1 (2) 1
Total MACE 4 (5) 14 (17) 0.01alues are given as number of patients (%).
MACE  major adverse cardiac events.14 days) statin therapy with placebo or usual care after an
cute coronary syndrome showed that statins do not de-
rease the incidence of death, myocardial infarction, or
troke, with a trend toward a reduction of unstable angina
17). However, this meta-analysis has included studies
nrolling mostly patients treated with a conservative strat-
gy, without early coronary intervention.
The ARMYDA trial (1) was a randomized study show-
ng the clinical benefit of pretreatment with statins in
atients undergoing PCI; however, this study enrolled only
atients with stable angina, and the protocol used (1-week
retreatment with atorvastatin) could not be applied to
nstable patients requiring an early invasive strategy. There-
ore, the ARMYDA study group has designed the
RMYDA-ACS trial to assess whether an acute loading
ith high-dose atorvastatin improves clinical outcome in
atients with acute coronary syndromes (unstable angina or
on–ST-segment elevation myocardial infarction) treated
Figure 2 ARMYDA-ACS Survival Curves
Actuarial curves of 30-day major adverse cardiac event (MACE)-free
survival in the 2 arms. PCI  percutaneous coronary intervention.
Figure 3 ARMYDA-ACS: Cardiac Marker Elevations
Incidence of postprocedural increase of creatine kinase-MB and
troponin-I 1 to 3 times and 3 times above the upper limits of normal.
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March 27, 2007:1272–8 Atorvastatin Improves PCI Results in ACSith PCI. Multivariable analysis indicates an 88% risk
eduction of MACE at 1 month in the treated arm. This is
much greater effect than that observed in other large
tudies using a high dose of statins in acute coronary
yndromes, albeit without early invasive strategy, such as
IRACL (Myocardial Ischemia Reducation with Aggres-
ive Cholesterol Lowering; 16% risk reduction of the
omposite primary cardiac end point) (18), A to Z (Aggra-
tat to Zocor; 25% risk reduction) (19) or PROVE-IT
Pravastatin or Atorvastatin Evaluation and Infection Ther-
py; 28% risk reduction) (20), all with a longer follow-up
eriod. Our study shows 70% reduction in the incidence of
eriprocedural myocardial infarction: according to these
ata, 10 patients should be treated with atorvastatin to avoid
case of myocardial infarction. Indeed, a significant pre-
ention of periprocedural myocardial injury, as measured by
ny postprocedural increase of cardiac markers (creatine
inase-MB and troponin-I), has been observed.
The possible mechanism(s) underlying the early protec-
ive effect of atorvastatin are unclear, but unlikely attribut-
ble to cholesterol-lowering effects, which require a longer
uration of treatment (21). Experimental evidence indicates
arious lipid-independent, pleiotropic effects of acute ator-
astatin treatment, such as improvement of endothelial
unction (22), vasodilation of coronary microvessels (23),
nd direct antithrombotic effect (24); atorvastatin bolus also
educes infarct size in a mouse model of ischemia-reperfusion
hrough a direct protective effect on myocardial cells (25).
inally, a prospective subanalysis on patients of the AR-
YDA trial has shown a significant attenuation of post-
CI increase of adhesion molecule levels in the atorvastatin
rm (2). In addition, anti-inflammatory actions of statins are
ell documented both in vitro (26) and in vivo (27); in
atients with acute coronary syndromes, atorvastatin signif-
cantly decreases levels of CRP during the acute phase
28,29) and enhances the decline in inflammation during
Figure 4 ARMYDA-ACS: Odds Ratios for 30-Day MACE
Results of multivariable analysis showing 88% major adverse cardiac event (MACE
0.05 to 0.50; p  0.004). ACE  angiotensin-converting enzyme; LVEF  left venollow-up (30). In the present study, atorvastatin did not teduce the postprocedural increase of CRP values in the
hole study population, but mostly in patients with higher
aseline levels of such markers; this suggests that the
nti-inflammatory effects of atorvastatin may be stronger in
atients with an enhanced baseline inflammatory status.
Our study included patients with non–ST-segment ele-
ation acute coronary syndromes requiring interventional
reatment; these results cannot be extrapolated directly to
atients with ST-segment elevation myocardial infarction,
r to those with unstable syndromes treated medically or
eceiving surgical revascularization. Furthermore, the
RMYDA-ACS trial included patients sent to an early
nvasive strategy, but not those undergoing emergency
evascularization; thus, it is unknown whether an immediate
ingle loading dose of atorvastatin may confer a protective
ffect also in the latter patients. Finally, patients on current
herapy with statins were excluded by study design; it is
nclear whether patients on chronic statin treatment may
ave a clinical benefit similar to that observed with acute
dministration. Indeed, in a rat model of ischemia/
eperfusion, the acute protective effect of atorvastatin on
yocardial injury wanes with a longer treatment, but this
ffect can be recaptured by a “reloading” given immediately
efore ischemia/reperfusion (31).
In the ARMYDA-ACS trial, only 24% of patients were
reated with glycoprotein IIb/IIIa antagonists, reflecting
ractice patterns in the participating centers, whereas all
atients received a 600-mg loading dose of clopidogrel
efore the procedure. The benefit of atorvastatin was inde-
endent of use of glycoprotein IIb/IIIa inhibitors, although
atients requiring such drugs had a significantly higher
ccurrence of adverse events at 30 days, probably because of
heir higher risk profile. On the other hand, the 5%
ncidence of myocardial infarction in the treated arm of the
RMYDA-ACS trial, similar to that observed in the
reduction at 30 days with atorvastatin (odds ratio 0.12, 95% confidence interval
ejection fraction; NSTEMI  non–ST-segment elevation myocardial infarction.) risk
tricularreatment arm of the more stable population of the original
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Atorvastatin Improves PCI Results in ACS March 27, 2007:1272–8RMYDA trial, may be caused by the protective effects of
he higher clopidogrel loading dose (4).
In conclusion, the present trial shows that a short-term
torvastatin pretreatment before PCI improves clinical out-
omes in patients with unstable angina and non–ST-
egment elevation myocardial infarction. If confirmed by
arger additional randomized studies, these findings may
upport the indication of “upstream” administration of
igh-dose statins in patients with acute coronary syndromes
reated with an early invasive strategy.
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APPENDIX
or a list of investigators who participated in the ARMYDA-ACS trial,
lease see the online version of this article.
